XT
CCCC icon

XTX Topco’s C4 Therapeutics CCCC Stock Holding History

XTX Topco’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$632K Buy
135,438
+88,287
+187% +$302K 0.01% 2236
2026
Q1 		$124K Sell
47,151
-57,307
-55% -$135K ﹤0.01% 3029
2025
Q4 		$200K Sell
104,458
-45,504
-30% -$108K 0.01% 2402
2025
Q3 		$333K Buy
149,962
+41,684
+38% +$100K 0.02% 1427
2025
Q2 		$155K Buy
108,278
+68,178
+170% +$99.2K 0.01% 1780
2025
Q1 		$64.2K Buy
+40,100
New +$120K ﹤0.01% 1956
2024
Q4 		– Sell
-84,951
Closed -$484K – 2348
2024
Q3 		$484K Buy
+84,951
New +$511K 0.04% 842
2024
Q1 		– Sell
-21,203
Closed -$120K – 1877
2023
Q4 		$120K Sell
21,203
-74,839
-78% -$171K 0.03% 1095
2023
Q3 		$179K Sell
96,042
-104,991
-52% -$320K 0.03% 1053
2023
Q2 		$553K Buy
201,033
+167,194
+494% +$537K 0.1% 308
2023
Q1 		$106K Buy
33,839
+19,685
+139% +$116K 0.02% 1091
2022
Q4 		$83.5K Buy
14,154
+1,605
+13% +$13.3K 0.02% 1016
2022
Q3 		$110K Buy
+12,549
New +$130K 0.03% 930

Other funds holding CCCC

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

XTX Topco's CCCC Position: Q2 2026 in Review

XTX Topco increased its C4 Therapeutics (CCCC) stake by 187% in Q2 2026, buying an estimated $302K and bringing the position to 135,438 shares worth $632K. The position accounts for 0.01% of the portfolio, ranked #2236.

XTX Topco first reported a position in CCCC in Q3 2022 and has held it in 13 quarters since. 147 funds tracked by Wall St. Rank hold CCCC as of Q2 2026.

  • XTX Topco held 135,438 shares of C4 Therapeutics worth $632K as of Q2 2026.
  • XTX Topco bought 88,287 C4 Therapeutics shares in Q2 2026, an estimated $302K.
  • C4 Therapeutics made up 0.01% of XTX Topco's portfolio in Q2 2026, its #2236 holding.
  • XTX Topco first reported a position in C4 Therapeutics in Q3 2022 and has held it in 13 quarters since.
  • 147 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2026.

Based on XTX Topco's 13F filing for Q2 2026, filed 14 Aug 2026.